Skip to main content
Call AIBook a demo

ICD-10-CM C90.21: Extramedullary plasmacytoma in remission

C90.21 is the billable ICD-10-CM code for extramedullary plasmacytoma in remission, in category C90 (Multiple myeloma and malignant plasma cell neoplasms) of the Malignant neoplasms of lymphoid, hematopoietic and related tissue section. As a principal diagnosis it groups to MS-DRG 820 Lymphoma and Leukemia with Major O.R. Procedures with MCC, MS-DRG 821 Lymphoma and Leukemia with Major O.R. Procedures with CC, MS-DRG 822 Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC (MDC 17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). It maps to HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) in CMS-HCC V28. As a secondary diagnosis it is a CC, excluded with 113 principal diagnoses. 24 LCD billing and coding articles list it as covered.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ICD-10-CM code descriptions: FY2027 (effective October 1, 2026); IPPS Table 5 (MS-DRG weights): v44 FY2027 (final rule + CN3) (effective October 1, 2026); ICD-10-CM to HCC mapping: PY2027 initial ICD-10-CM mappings (dates of service 2026) (payment year 2027); Medicare Coverage Database billing and coding articles: MCD release October 8, 2026 (effective October 4, 2026). Next CMS release: FY2028 code files, effective October 1, 2027 for the ICD-10-CM code descriptions; FY2028 final rule (August 2027), effective October 1, 2027; an April 1 interim grouper update when CMS issues one for the IPPS Table 5 (MS-DRG weights); PY2028 advance notice (February 2027) and the PY2027 midyear final mapping (spring 2027) for the ICD-10-CM to HCC mapping; weekly, every Thursday for the Medicare Coverage Database billing and coding articles.

Code
C90.21
billable FY2027 ICD-10-CM code
Category
C90 Multiple myeloma and malignant plasma cell neoplasms
Chapter
2: Neoplasms (C00-D49)
CC/MCC (MS-DRG v44)
CC
CMS-HCC V28
HCC 19
POA reporting
Required

Tabular list notes for C90.21

The tabular list has no notes on C90.21 itself; the notes below apply from its parent headings.

Inherited from C90 (Multiple myeloma and malignant plasma cell neoplasms)

Excludes1 (never coded together)
  • personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (Z85.79)

MS-DRG grouping when C90.21 is the principal diagnosis

MS-DRG v44 groups for C90.21 as principal diagnosis
MDCMS-DRGs
17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms820821822823824825840841842

The final group also depends on procedures, secondary diagnoses and discharge status; the MS-DRG lookup for C90.21 shows the full grouping logic.

CC/MCC status and inpatient edits

As a secondary diagnosis, C90.21 is a CC under MS-DRG v44, unless the principal diagnosis is one of the 113 codes in its exclusion list. Check C90.21 against a principal diagnosis.

  • Present on admission: a POA indicator is required on inpatient claims.

CMS-HCC V28 risk adjustment

In the PY2027 mapping, C90.21 maps to HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers). The HCC lookup shows the RAF weight and the hierarchy.

LCD billing and coding articles that list C90.21

24 current Medicare billing and coding articles list C90.21 among the diagnoses that support medical necessity for the services they cover.

For teams evaluating QuickIntell software

Evaluate software for diagnosis coding review

If your team codes diagnoses at volume, review how QuickCode supports qualified coder review of documentation, specificity queries and the billing handoff. Confirm the code sets, settings and reviewer responsibilities during evaluation; a code reference is not a coding determination for a patient.

Evaluate QuickCode for diagnosis codingSee risk adjustment review
Book a software demoAsk about a software workflow

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does ICD-10-CM C90.21 mean?

C90.21 means extramedullary plasmacytoma in remission. It is one of 12 billable codes under C90, multiple myeloma and malignant plasma cell neoplasms.

Which MS-DRG does C90.21 group to?

As the principal diagnosis, C90.21 groups to MS-DRG 820 Lymphoma and Leukemia with Major O.R. Procedures with MCC, MS-DRG 821 Lymphoma and Leukemia with Major O.R. Procedures with CC, MS-DRG 822 Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC (MDC 17 MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms) under MS-DRG v44, before procedures and secondary diagnoses are applied.

Does C90.21 map to an HCC?

Yes: HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers, in the PY2027 CMS-HCC V28 mapping.

Is C90.21 a CC or MCC?

C90.21 is a CC under MS-DRG v44; 113 principal diagnoses exclude it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The descriptor and notes are reproduced from the FY2027 ICD-10-CM files; MS-DRG, CC/MCC and HCC facts come from the CMS FY2027 and PY2027 tables. Code from the medical record and the ICD-10-CM Official Guidelines. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.